Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Breakthrough Retinal Implant Restores Vision in Patients with Advanced Macular Degeneration

Breakthrough Retinal Implant Restores Vision in Patients with Advanced Macular Degeneration

Science Corp.'s PRIMA retinal implant system has achieved a significant milestone in the treatment of age-related macular degeneration (AMD), offering new hope for millions suffering from this debilitating eye condition. A recent study published in The New England Journal of Medicine demonstrates remarkable improvements in vision for patients with geographic atrophy, an advanced form of AMD.

NoahAI News10/21/2025
Biolinq's Innovative CGM Technology Receives FDA Green Light

Biolinq's Innovative CGM Technology Receives FDA Green Light

Biolinq, a diabetes tech startup, has received FDA authorization to market its first glucose sensor, marking a significant advancement in continuous glucose monitoring (CGM) technology. The device, named Biolinq Shine, introduces novel design features and sensing mechanisms that could potentially reshape the landscape of diabetes management.

NoahAI News10/21/2025
Roche's Gazyva Receives FDA Approval for Lupus Nephritis, Expanding Beyond Cancer Indications

Roche's Gazyva Receives FDA Approval for Lupus Nephritis, Expanding Beyond Cancer Indications

Roche's anti-CD20 antibody Gazyva (obinutuzumab) has received FDA approval for the treatment of adults with lupus nephritis, marking its first indication outside of oncology. This significant development represents a major step forward in the management of this serious autoimmune condition.

NoahAI News10/21/2025
Alto Neuroscience Accelerates Depression Drug Development with $50 Million Boost

Alto Neuroscience Accelerates Depression Drug Development with $50 Million Boost

Alto Neuroscience, a psychiatry drug specialist, has announced plans to expedite the development of its potential depression medicine, ALTO-207. The company's shares more than doubled following the news, reaching a peak of $12.19 on Monday, a level not seen since negative results from another drug study nearly a year ago.

NoahAI News10/21/2025
Replimune's RP1 Melanoma Drug Gains New Life with FDA Resubmission Acceptance

Replimune's RP1 Melanoma Drug Gains New Life with FDA Resubmission Acceptance

In a surprising turn of events, Replimune announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted a resubmission for RP1, its advanced melanoma drug candidate. This development comes just one month after the company had set low expectations for the drug's future, following a previous rejection by the regulatory agency.

NoahAI News10/21/2025
HHS Continues Layoffs Despite Court Order as Government Shutdown Enters Fourth Week

HHS Continues Layoffs Despite Court Order as Government Shutdown Enters Fourth Week

The U.S. Department of Health and Human Services (HHS) is proceeding with plans to lay off nearly 1,000 employees, despite a federal judge's order temporarily halting shutdown-related layoffs. This development comes as the government shutdown enters its fourth week, with negotiations between Democrats and Republicans at an impasse over healthcare subsidies.

NoahAI News10/21/2025
Akeso and Summit's Ivonescimab Shows Promise in First-Line NSCLC Treatment

Akeso and Summit's Ivonescimab Shows Promise in First-Line NSCLC Treatment

Akeso and Summit Therapeutics' novel PD-1/VEGF bispecific antibody, ivonescimab, has demonstrated significant efficacy in first-line treatment of non-small cell lung cancer (NSCLC), according to data presented at the 2025 European Society for Medical Oncology (ESMO) congress in Berlin.

NoahAI News10/21/2025
Acquisition Rumors Spark Nektar Therapeutics Stock Surge Amid Ongoing Eli Lilly Lawsuit

Acquisition Rumors Spark Nektar Therapeutics Stock Surge Amid Ongoing Eli Lilly Lawsuit

Nektar Therapeutics' shares experienced a significant uptick following rumors of a potential acquisition, with speculation pointing to Eli Lilly as the prospective buyer. This development comes against the backdrop of a complex history between the two companies, including a terminated partnership and an ongoing lawsuit.

NoahAI News10/21/2025
Novo Nordisk Secures Cardiovascular Expansion for Rybelsus Amid Mixed News for the Company

Novo Nordisk Secures Cardiovascular Expansion for Rybelsus Amid Mixed News for the Company

Novo Nordisk has received approval for a significant label expansion for its oral semaglutide pill, Rybelsus, allowing its use in reducing cardiovascular risks in type 2 diabetes patients. This development comes as the pharmaceutical giant navigates through a series of challenges, including manufacturing issues and strategic restructuring.

NoahAI News10/21/2025
Boston Scientific to Acquire Nalu Medical for $533M, Expanding Neuromodulation Portfolio

Boston Scientific to Acquire Nalu Medical for $533M, Expanding Neuromodulation Portfolio

Boston Scientific has announced its agreement to acquire Nalu Medical, a private company specializing in neurostimulation technology for chronic pain management. The deal, valued at $533 million, will see Boston Scientific purchase the remaining equity in Nalu Medical, building on their existing investment relationship that began in 2017.

NoahAI News10/21/2025
FDA Approves Glaukos' Epioxa for Rare Eye Disorder Keratoconus

FDA Approves Glaukos' Epioxa for Rare Eye Disorder Keratoconus

The U.S. Food and Drug Administration (FDA) has granted approval to Glaukos Corporation's Epioxa, a novel therapy for the treatment of keratoconus, a rare and potentially blinding eye disorder. This groundbreaking development offers patients a non-invasive alternative to traditional corneal cross-linking procedures, potentially revolutionizing the management of this debilitating condition.

NoahAI News10/21/2025
BioNTech Halts Further Development of Cancer Vaccine in Late-Stage Melanoma

BioNTech Halts Further Development of Cancer Vaccine in Late-Stage Melanoma

BioNTech, the German pharmaceutical company known for its mRNA technology, has announced it will not pursue further clinical trials of its BNT111 cancer vaccine candidate in late-stage refractory melanoma. This decision, revealed at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, marks a significant shift in the company's oncology strategy.

NoahAI News10/21/2025
«1...313233...67»